These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 27646833)

  • 1. The Effects of Pharmacological Compounds on Beat Rate Variations in Human Long QT-Syndrome Cardiomyocytes.
    Kuusela J; Kim J; Räsänen E; Aalto-Setälä K
    Stem Cell Rev Rep; 2016 Dec; 12(6):698-707. PubMed ID: 27646833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a novel KCNQ1 mutation for type 1 long QT syndrome and assessment of the therapeutic potential of a novel IKs activator using patient-specific induced pluripotent stem cell-derived cardiomyocytes.
    Ma D; Wei H; Lu J; Huang D; Liu Z; Loh LJ; Islam O; Liew R; Shim W; Cook SA
    Stem Cell Res Ther; 2015 Mar; 6(1):39. PubMed ID: 25889101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Large-Scale Simulation of the Phenotypical Variability Induced by Loss-of-Function Long QT Mutations in Human Induced Pluripotent Stem Cell Cardiomyocytes.
    Paci M; Casini S; Bellin M; Hyttinen J; Severi S
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30428582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells.
    Ma D; Wei H; Zhao Y; Lu J; Li G; Sahib NB; Tan TH; Wong KY; Shim W; Wong P; Cook SA; Liew R
    Int J Cardiol; 2013 Oct; 168(6):5277-86. PubMed ID: 23998552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes.
    Kitaguchi T; Moriyama Y; Taniguchi T; Maeda S; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Miyamoto N
    J Pharmacol Toxicol Methods; 2017; 85():73-81. PubMed ID: 28163191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Availability of human induced pluripotent stem cell-derived cardiomyocytes in assessment of drug potential for QT prolongation.
    Nozaki Y; Honda Y; Tsujimoto S; Watanabe H; Kunimatsu T; Funabashi H
    Toxicol Appl Pharmacol; 2014 Jul; 278(1):72-7. PubMed ID: 24742750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the CACNA1C-R518C Missense Mutation in the Pathobiology of Long-QT Syndrome Using Human Induced Pluripotent Stem Cell Cardiomyocytes Shows Action Potential Prolongation and L-Type Calcium Channel Perturbation.
    Estes SI; Ye D; Zhou W; Dotzler SM; Tester DJ; Bos JM; Kim CSJ; Ackerman MJ
    Circ Genom Precis Med; 2019 Aug; 12(8):e002534. PubMed ID: 31430211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling Short QT Syndrome Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    El-Battrawy I; Lan H; Cyganek L; Zhao Z; Li X; Buljubasic F; Lang S; Yücel G; Sattler K; Zimmermann WH; Utikal J; Wieland T; Ravens U; Borggrefe M; Zhou XB; Akin I
    J Am Heart Assoc; 2018 Mar; 7(7):. PubMed ID: 29574456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological enhancement of repolarization reserve in human induced pluripotent stem cells derived cardiomyocytes.
    Treat JA; Goodrow RJ; Bot CT; Haedo RJ; Cordeiro JM
    Biochem Pharmacol; 2019 Nov; 169():113608. PubMed ID: 31465775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrophysiological Characteristics of Human iPSC-Derived Cardiomyocytes for the Assessment of Drug-Induced Proarrhythmic Potential.
    Yamamoto W; Asakura K; Ando H; Taniguchi T; Ojima A; Uda T; Osada T; Hayashi S; Kasai C; Miyamoto N; Tashibu H; Yoshinaga T; Yamazaki D; Sugiyama A; Kanda Y; Sawada K; Sekino Y
    PLoS One; 2016; 11(12):e0167348. PubMed ID: 27923051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The electrophysiological effects of cardiac glycosides in human iPSC-derived cardiomyocytes and in guinea pig isolated hearts.
    Guo L; Qian JY; Abrams R; Tang HM; Weiser T; Sanders MJ; Kolaja KL
    Cell Physiol Biochem; 2011; 27(5):453-62. PubMed ID: 21691062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electrophysiological characteristics and pharmacological sensitivity of two lines of human induced pluripotent stem cell derived cardiomyocytes coming from two different suppliers.
    Goineau S; Castagné V
    J Pharmacol Toxicol Methods; 2018; 90():58-66. PubMed ID: 29274391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex-Related Differences in Drug-Induced QT Prolongation and Torsades de Pointes: A New Model System with Human iPSC-CMs.
    Huo J; Wei F; Cai C; Lyn-Cook B; Pang L
    Toxicol Sci; 2019 Feb; 167(2):360-374. PubMed ID: 30247688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Induced Pluripotent Stem Cell-Derived Engineered Heart Tissue as a Sensitive Test System for QT Prolongation and Arrhythmic Triggers.
    Lemoine MD; Krause T; Koivumäki JT; Prondzynski M; Schulze ML; Girdauskas E; Willems S; Hansen A; Eschenhagen T; Christ T
    Circ Arrhythm Electrophysiol; 2018 Jul; 11(7):e006035. PubMed ID: 29925535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene- and variant-specific efficacy of serum/glucocorticoid-regulated kinase 1 inhibition in long QT syndrome types 1 and 2.
    Giannetti F; Barbieri M; Shiti A; Casini S; Sager PT; Das S; Pradhananga S; Srinivasan D; Nimani S; Alerni N; Louradour J; Mura M; Gnecchi M; Brink P; Zehender M; Koren G; Zaza A; Crotti L; Wilde AAM; Schwartz PJ; Remme CA; Gepstein L; Sala L; Odening KE
    Europace; 2023 May; 25(5):. PubMed ID: 37099628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elucidating arrhythmogenic mechanisms of long-QT syndrome CALM1-F142L mutation in patient-specific induced pluripotent stem cell-derived cardiomyocytes.
    Rocchetti M; Sala L; Dreizehnter L; Crotti L; Sinnecker D; Mura M; Pane LS; Altomare C; Torre E; Mostacciuolo G; Severi S; Porta A; De Ferrari GM; George AL; Schwartz PJ; Gnecchi M; Moretti A; Zaza A
    Cardiovasc Res; 2017 Apr; 113(5):531-541. PubMed ID: 28158429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-Mediated Shortening of Action Potentials in LQTS2 Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Duncan G; Firth K; George V; Hoang MD; Staniforth A; Smith G; Denning C
    Stem Cells Dev; 2017 Dec; 26(23):1695-1705. PubMed ID: 28992755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complex aberrant splicing in the induced pluripotent stem cell-derived cardiomyocytes from a patient with long QT syndrome carrying KCNQ1-A344Aspl mutation.
    Wuriyanghai Y; Makiyama T; Sasaki K; Kamakura T; Yamamoto Y; Hayano M; Harita T; Nishiuchi S; Chen J; Kohjitani H; Hirose S; Yokoi F; Gao J; Chonabayashi K; Watanabe K; Ohno S; Yoshida Y; Kimura T; Horie M
    Heart Rhythm; 2018 Oct; 15(10):1566-1574. PubMed ID: 29857160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSAHi study: Evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia--effects of 7 reference compounds at 10 facilities.
    Kitaguchi T; Moriyama Y; Taniguchi T; Ojima A; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Morita M; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Tanaka K; Washio I; Miyamoto N
    J Pharmacol Toxicol Methods; 2016; 78():93-102. PubMed ID: 26657830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational prediction of drug response in short QT syndrome type 1 based on measurements of compound effect in stem cell-derived cardiomyocytes.
    Jæger KH; Wall S; Tveito A
    PLoS Comput Biol; 2021 Feb; 17(2):e1008089. PubMed ID: 33591962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.